Orion has launched Vantas (histrelin) for the palliative treatment of advanced prostate cancer.

Vantas (histrelin) is a depot formulation of a luteinising-hormone releasing hormone (LHRH) analogue. Inserted subcutaneously into the upper arm, the implant delivers an average of 50 micrograms of histrelin acetate daily for 12 months. Histrelin inhibits LH secretion leading to a fall in circulating testosterone levels promoting tumour regression and symptom improvement.

Patients with metastatic vertebral lesions and/or urinary tract obstruction should be closely monitored for exacerbation of symptoms during the first few weeks after Vantas implantation.

View Vantas drug record

Further information: Orion

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

Avoid routinely offering antidepressants for 'less severe' depression, says NICE in draft guidance
Products coming soon - live tracker

Products coming soon - live tracker

EXCLUSIVE TO SUBSCRIBERS Monitor forthcoming UK drug...

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Intal asthma inhaler to be discontinued

Intal asthma inhaler to be discontinued

The asthma preventer inhaler Intal (sodium cromoglicate)...